Nisa Investment Advisors LLC Decreases Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

Nisa Investment Advisors LLC trimmed its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 17.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,955 shares of the biotechnology company's stock after selling 4,544 shares during the period. Nisa Investment Advisors LLC's holdings in United Therapeutics were worth $6,460,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Cerity Partners LLC lifted its position in shares of United Therapeutics by 30.4% during the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after acquiring an additional 2,702 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of United Therapeutics by 11.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after acquiring an additional 376 shares during the period. Korea Investment CORP lifted its position in shares of United Therapeutics by 6.2% during the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock valued at $13,863,000 after acquiring an additional 2,300 shares during the period. Nepsis Inc. raised its holdings in shares of United Therapeutics by 6.7% during the 1st quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company's stock worth $18,057,000 after buying an additional 3,653 shares in the last quarter. Finally, ExodusPoint Capital Management LP acquired a new position in shares of United Therapeutics during the 4th quarter worth $1,899,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

Shares of UTHR stock traded down $4.64 on Friday, hitting $295.52. The company had a trading volume of 300,699 shares, compared to its average volume of 444,965. The firm has a market cap of $13.33 billion, a P/E ratio of 11.79, a P/E/G ratio of 6.57 and a beta of 0.53. The stock's 50-day moving average is $301.04 and its two-hundred day moving average is $320.31. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same period in the previous year, the company posted $6.17 earnings per share. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. Equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Bank of America lowered their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday, June 11th. Cantor Fitzgerald assumed coverage on United Therapeutics in a report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target for the company. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Wells Fargo & Company reissued an "equal weight" rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Finally, Morgan Stanley lowered their price target on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a report on Thursday. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $383.08.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 12,000 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the sale, the chief financial officer directly owned 8,118 shares of the company's stock, valued at approximately $2,641,353.66. This trade represents a 59.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Nilda Mesa sold 645 shares of the stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the sale, the director directly owned 4,883 shares of the company's stock, valued at $1,416,021.17. The trade was a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 76,681 shares of company stock worth $22,813,739 in the last 90 days. Company insiders own 10.30% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.